Common molecular signature of two neuroprotective agents

ABSTRACT: The current lack of proven pharmacological treatment options for traumatic brain injury (TBI) patients reflects the poor translation of successful preclinical studies in clinical trials. This may be due to poor choice of therapeutic agents based on incomplete knowledge of critical elements of neuroprotection. Our goal is to expedite discovery and translation of therapeutic agents that can improve functional outcome by identifying the common molecular profile of neuroprotective drugs. Since damage to the hippocampus is associated with TBI-induced deficits in learning and memory, we analyzed of the hippocampal transcriptional profiles of TBI rats treated with two clinically used drugs metyrapone and carbenoxolone, which have been shown to improve cognitive deficits in previous studies. Despi

ORGANISM(S): Rattus norvegicus

SUBMITTER: Michael Falduto 

PROVIDER: E-GEOD-31357 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress